Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by PWIB123on Sep 25, 2024 2:27pm
171 Views
Post# 36240702

$30/Share

$30/ShareI have shares that I own with a cost basis as high as $28.  End of year is coming.  Unfortunately, I do not need any tax write-offs, so I won't be liquidating any shares to offset gains.  I've got accrued losses from the past that will offset my gains for this year.  I am repositioning my portfolio, however.  We used to dream of a day when the stock could fly up to $200/share.  Those days are gone, but does anyone believe it is possible to see THTX hit $30/share if the oncology platform shows success as the end of this year.  I've dollar cost averaged down in most of my accounts, but still have way too many at that ridiculous $28/share price after management made all those mistakes.  There is zero excitement surrounding the stock.  Not sure how you guys feel, but I know several of you feel stuck like me.  

What are your price targets?

I personally think the market completely distrusts management.  How long are you willing to continue to hold if we do not see any significant share price appreciation even if we get good results from TH-1902?

I've lost hope in TH-1902, but would hope that they could at least bring the company profitable again.  I've seen some of those estimates on share value in the past.  I mean, I would take $3-$4/share over where we are at today, but this is not what I had in mind when I invested in THTX.  If the best we get is a crappy but profitable company, how should we be thinking about an exit price?

Any other thoughts I should consider?  I've said I'll just leave what I have left, since it's not much, and let it ride, but if at the end of the year, we still see nothing, it may be time to move on.  Huge losses accrued here, and I hate it, but it is what it is.  I've got a future opportunity to offset these losses with gains in real estate I own, so the tax strategy is still in play here for me over the next couple of years.
<< Previous
Bullboard Posts
Next >>